October 23–27, 2026 · Madrid · 2854 items
10 people · 10 posts · 5 abstracts
Heat now 5·Peak in the comparable set 5 (Oct 24 23:00)·Change over 24h in the comparable set –·Participants now 5
Bevacizumab, a monoclonal antibody against VEGF, established its role as a combination-therapy backbone through multiple published phase III trials: in previously untreated metastatic colorectal cancer, adding bevacizumab to IFL chemotherapy improved median overall survival from 15.6 to 20.3 months, with an HR for death of 0.66 [1]; in recurrent or advanced non-small-cell lung cancer, adding bevacizumab to paclitaxel-carboplatin extended median survival from 10.3 to 12.3 months (HR 0.79) [4]. It later became a platform for immuno-oncology combinations: atezolizumab plus bevacizumab versus sorafenib in unresectable hepatocellular carcinoma yielded an HR for death of 0.58 (95% CI 0.42–0.79) [2], and the regimen is listed among six systemic therapies approved for HCC on phase III evidence [3]; in metastatic nonsquamous NSCLC, a phase III also directly compared atezolizumab plus bevacizumab plus carboplatin plus paclitaxel against bevacizumab plus chemotherapy [6]. This cross-tumor, cross-partner backbone status is precisely why this meeting's updates centered on dosing schedule and novel combinations.
The heaviest coverage went to PRABITAS in Japan: a pragmatic, multicentre, open-label, randomised, phase 3 non-inferiority trial published simultaneously in The Lancet, comparing biweekly (14-day) versus conventional (28-day) trifluridine/tipiracil (TAS-102/FTD-TPI) plus bevacizumab in refractory metastatic colorectal cancer. The numbers as posted: ORR 2% in both arms, mPFS 3.9 versus 3.9 months; the direction of mOS was recorded inconsistently across two posts, written as 10.3 versus 11.3 months in one and 11.3 versus 10.3 months (HR 0.93) in the other, both pointing to OS non-inferiority. The real difference was toxicity: grade ≥3 neutropenia fell from 39% to 13%, summarized by posters as similar efficacy, less toxicity, and support for the biweekly schedule.
Two earlier-stage readouts on the same bevacizumab base also appeared. First, updated phase I data on Temab-A (ABBV-400) plus bevacizumab in 3L+ colorectal cancer showed mOS of 14.7 months versus 10.2 months with FTD-TPI + Bev, HR 0.62 (95% CI 0.33–1.18), published simultaneously in Annals of Oncology and described by the poster as an encouraging ADC signal. Second, INCB123667 plus bevacizumab achieved a 48% response rate in a phase 1 study of heavily pretreated, cyclin E1–overexpressing, platinum-resistant recurrent epithelial ovarian cancer, with responses observed even after prior PARP inhibitor and bevacizumab treatment. In terms of advancing existing knowledge, PRABITAS elevates the same-drug-less-toxicity scheduling question to phase III non-inferiority evidence, while the other two suggest bevacizumab's partners are extending from chemotherapy [1][4] and immunotherapy [2][6] to ADCs and biomarker-selected targeted combinations.
The limitations are equally clear: both Temab-A and INCB123667 are phase I, with sample sizes and confirmatory trial plans undisclosed; the former's HR confidence interval crosses 1, and the nature of the FTD-TPI + Bev comparison is undisclosed; PRABITAS was open-label and conducted only in Japan, so extrapolation of the biweekly schedule's benefit to other healthcare settings remains to be confirmed.
Iparomlimab and tuvonralimab (QL1706) plus chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (R/M CC): Results from a double-blind, randomized, placebo-controlled phase
https://esmocongress.esmo.orgLong-term follow-up of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab (Bev) vs standard of care (SOC) in patients (pts) with 3L+ colorectal cancer (CRC): Updated results of a phase 1 study
https://esmocongress.esmo.orgOutcomes with trifluridine/tipiracil plus bevacizumab across age groups in metastatic colorectal cancer: The BeTAS study
https://esmocongress.esmo.orgBiweekly versus conventional trifluridine/tipiracil plus bevacizumab for refractory metastatic colorectal cancer: The pragmatic phase 3 PRABITAS trial
https://esmocongress.esmo.orgFinal overall survival (OS) results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase 3 trial of first-line atezolizumab (atezo), chemotherapy (CT) and bevacizumab (bev) for metastatic, persistent or recurrent cervic
https://esmocongress.esmo.orgTemab-A (ABBV-400) + bevacizumab in 3L+ CRC: updated phase I data
Sometimes less is more in oncology!
The phase 3 PRABITAS trial showed that a 14-day schedule of trifluridine-tipiracil plus bevacizumab was non-inferior to the 28-day schedule for overall survival. Conducted in refractory metastatic colorectal cancer, the 14-day schedule had lower haematological and gastrointestinal toxicity; the results support the simplified schedule as the new standard for this combination.
This practical review recommends corticosteroids only as a temporary measure for mass effect in neuro-oncology patients, at the lowest effective dose once or twice daily (the second dose no later than early afternoon), tapered off as soon as possible. Long-term use increases adverse effects across endocrine, immune, dermatologic, gastrointestinal, orthopedic, and neuropsychiatric systems, and weakens the efficacy of immunotherapy and chemoradiation. Steroid-sparing options such as bevacizumab have been used to reduce toxicity, and steroid effects on tumor response are now formally incorporated into imaging response assessment.
Corticosteroids are an important treatment for neuro-oncology patients and should be used only as a temporary measure to relieve tumor mass effect, dosed once or twice daily with the second dose no later than early afternoon. Long-term use can affect multiple systems including endocrine, immune, and gastrointestinal, increase complications, and may weaken the efficacy of immunotherapy and chemoradiation; steroid-sparing regimens such as bevacizumab have been used to reduce toxicity. The review recommends the lowest effective dose with tapering as soon as possible, with special consideration of steroid effects during immunotherapy and imaging response assessment.